2026-04-14T06:11:38Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4631352026-03-13T10:23:30Zcom_2072_98col_2072_378192

urn:hdl:2072/463135 Growth differentiation factor 15 (Gdf-15) : A novel biomarker associated with poorer respiratory function in covid-19 Alserawan, Leticia Peñacoba, Patricia Orozco, Sandra Castillo, Diego Ortiz, Esther Martinez-Martinez, Laura Moga, Esther Domingo Pedrol, Pedro Castellvi, Ivan Juarez, Candido Mariscal, Anaís Universitat Autònoma de Barcelona GDF-15 COVID-19 Respiratory function Inflammation Biomarker It is essential to find new biomarkers for severity stratification of patients with coronavirus disease (COVID-19). Growth differentiation factor 15 (GDF-15) is upregulated in pathological conditions that involve inflammation and/or oxidative stress. We determined circulating levels of GDF-15 and correlated them with clinical and laboratory parameters reflecting severity in 84 patients with COVID-19, finding that GDF-15 levels were higher in both patients than in 20 healthy controls and were higher in patients with poorer respiratory function. GDF-15 levels also correlated with interleukin-6, C-reactive protein, ferritin and D-dimer levels and with neutrophilia and lymphopenia. Of all the analysed biomarkers, GDF-15 showed the best area under the receiver operating characteristics curve in identifying patients with poor respiratory function. In conclusion, our data support GDF-15 as a biomarker associated with pulmonary impairment in COVID-19 and so can potentially be useful in stratifying COVID-19 cases by severity. 2021 Article Diagnostics ; Vol. 11 Núm. 11 (november 2021), p. 1998 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/